Briobacept  (Synonyms: BR 3FC)

Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA)^[1][2].

BLyS (BAFF)^[1]

Briobacept 阻断循环的 BLyS，从而抑制 B 细胞活化，促进 B 细胞凋亡^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Briobacept (100 μg/小鼠; 腹腔注射; 共 5 天) 抑制野生型小鼠体内 NF-κB2 激活的基础水平 ^[4]。
Briobacept (100 μg/小鼠; 腹腔注射; 每周 3 次, 共 5 周) 在 NZB/WF1 小鼠中抑制 p52 的产生和自发性狼疮样疾病的发展^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

869881-54-9

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2). Reumatol Clin. 2012 Sep-Oct;8(5):263-9.  [Content Brief]

  [2]. Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22(33):3152-3154.

  [3]. La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10(11):1555-61.  [Content Brief]

  [4]. Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17(4):515-24.  [Content Brief]